Filing Flows › Seres Therapeutics (MCRB) › Q2 2026
Seres Therapeutics (MCRB) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Seres Therapeutics (MCRB) reported revenue of $736K for the second quarter 2026 (Q2 2026) and +106% from the quarter before.
Seres Therapeutics, Q2 2026: revenue $736K, net earnings $4.6M, operating cash flow −$22.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $736K | +106% | — |
| Operating profit | −$21.3M | — | — |
| Net earnings | $4.6M | — | — |
| Operating cash flow | −$22.4M | — | — |
What changed
Revenue was $736K in Q2 2026, up 106% from the previous quarter.
Operating costs exceeded revenue by $21.3M, an operating margin of -2890.4%. Net earnings were $4.6M. The effective tax rate was 0.0%. Non-operating items added $25.9M, 564% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$22.4M. Non-cash charges added back $670K of depreciation and amortization and $1.7M of share-based compensation. Working capital and other items used $29.4M.
Questions
What was Seres Therapeutics' revenue in the second quarter 2026?
Seres Therapeutics (MCRB) reported revenue of $736K for the second quarter 2026 (Q2 2026) and +106% from the quarter before.
Source: Seres Therapeutics 10-Q on SEC EDGAR.